FDA Speeds Possible Second-Line Treatment for Mesothelioma
The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such…
The post FDA Speeds Possible Second-Line Treatment for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.